RAPLODAPT

Ploidy change as a rapid mechanism of adaptation

 Coordinatore TEL AVIV UNIVERSITY 

Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.

 Nazionalità Coordinatore Israel [IL]
 Totale costo 2˙365˙000 €
 EC contributo 2˙365˙000 €
 Programma FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call ERC-2013-ADG
 Funding Scheme ERC-AG
 Anno di inizio 2014
 Periodo (anno-mese-giorno) 2014-01-01   -   2018-12-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITY OF ROCHESTER

 Organization address address: "ELMWOOD AVENUE, BOX EHSC 601"
city: ROCHESTER NY
postcode: 14642

contact info
Titolo: Ms.
Nome: Amanda
Cognome: Augustin
Email: send email
Telefono: 18582733349
Fax: 15852760232

US (ROCHESTER NY) beneficiary 39˙573.86
2    TEL AVIV UNIVERSITY

 Organization address address: RAMAT AVIV
city: TEL AVIV
postcode: 69978

contact info
Titolo: Ms.
Nome: Lea
Cognome: Pais
Email: send email
Telefono: 97236408774

IL (TEL AVIV) hostInstitution 2˙325˙426.20
3    TEL AVIV UNIVERSITY

 Organization address address: RAMAT AVIV
city: TEL AVIV
postcode: 69978

contact info
Titolo: Prof.
Nome: Judith
Cognome: Berman
Email: send email
Telefono: 97236407633
Fax: 97236409697

IL (TEL AVIV) hostInstitution 2˙325˙426.20

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

drugr    prevalent    drug    haploids    generation    persistence    genome    appearance    diversity    insights    pathogens    fungal    ploidy    genomic    resistance    rapid    albicans   

 Obiettivo del progetto (Objective)

'Fungi are particularly challenging pathogens; because they and their human hosts are eukaryotes. We will study how new traits such as drugR arise rapidly using Candida albicans, the most prevalent fungal pathogen of humans. The work explores the ground-breaking concept that alterations in genome ploidy are prevalent in drugR isolates because these genome states promote persistence and drug resistance. We recently found that C. albicans, thought to be an “obligate diploid”, can form haploids. This represents a major paradigm shift both technologically and conceptually. We are poised to exploit this unique opportunity to reinvent genomic approaches for C. albicans by leveraging next generation sequencing, high throughput analyses and more traditional genetics. Because haploids are much less fit than heterozygous diploids, our working hypothesis is that changes in ploidy, including whole genome ploidy and aneuploidy, occur frequently under drug stress and that they make major contributions to the rapid appearance of genotypic and phenotypic diversity, in part by promoting persistence. The objectives of this proposal are to develop next-generation technologies that leverage haploids; to characterize the conditions and genes that promote ploidy transitions, especially in the presence of drug, in vitro and in vivo and to analyze their fitness consequences. This multi-disciplinary research program will integrate = approaches at the genetic, genomic, molecular, cellular and population levels and includes computational approaches to model evolutionary processes. The project will lead to unparalleled advances in tools for the research community, and important insights concerning how diversity arises rapidly. It will assist in efforts to design diagnostic and therapeutic strategies for preventing and treating fungal diseases, prividing insights into the rapid appearance of drug resistance in eukaryotic pathogens, and chemotherapy resistance in cancer cells.'

Altri progetti dello stesso programma (FP7-IDEAS-ERC)

ELNOX (2008)

Elemental nitrogen oxidation – A new bacterial process in the nitrogen cycle

Read More  

NOMBQUANT (2014)

Novel phases in quantum gases: from few-body to many-body physics

Read More  

POCUMINT (2014)

Proof Of Concept Use of MTH1 Inhibitors as New Treatments for cancer

Read More